GlobeNewswire: BiPar Sciences Contains the last 10 of 16 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:42:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2009/07/17/400928/169195/en/BSI-201-Enters-Phase-3-in-Metastatic-Triple-Negative-Breast-Cancer.html?f=22&fvtc=4&fvtv=7548BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer2009-07-17T05:00:00Z<![CDATA[Recruitment Into Pivotal Phase 3 Study Initiated Just 2 Months After Striking Phase 2 Results PARIS and SOUTH SAN FRANCISCO, Calif., July 17, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its wholly owned subsidiary, BiPar Sciences, today announced the initiation of the pivotal Phase 3 trial for BSI-201 in combination with chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC), defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. BSI-201 is a novel, investigational, targeted therapy which inhibits poly (ADP-ribose) polymerase (PARP1), an enzyme involved in DNA damage repair.
]]>https://www.globenewswire.com/news-release/2009/05/31/398479/166386/en/Investigational-Cancer-Drug-BSI-201-Showed-Clinical-Benefit-in-62-of-Patients-With-Triple-Negative-Metastatic-Breast-Cancer-and-Significantly-Prolonged-Survival.html?f=22&fvtc=4&fvtv=7548Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival2009-05-31T12:30:00Z<![CDATA[Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting PARIS and BRISBANE, Calif., May 31, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage.
]]>https://www.globenewswire.com/news-release/2009/05/20/1352/0/de/In-Pr%C3%BCfung-befindlicher-PARP-Inhibitor-von-BiPar-Sciences-BSI-201-im-Scheinwerferlicht-der-ASCO-Vollversammlung.html?f=22&fvtc=4&fvtv=7548In Prüfung befindlicher PARP-Inhibitor von BiPar Sciences, BSI-201, im Scheinwerferlicht der ASCO-Vollversammlung2009-05-20T07:00:00Z<![CDATA[BRISBANE, Kalifornien und PARIS, 20. Mai 2009 (GLOBE NEWSWIRE) -- Die
Ergebnisse der Phase II einer klinischen Studie von BiPar Science - einem
Tochterunternehmen im Besitz von sanofi-aventis - über den führenden
PARP-Inhibitor BSI-201 werden in der Vollversammlung beim 45. Jahrestreffen der
American Society of Clinical Oncology (ASCO) in Orlando, FL vorgestellt.
Bei der Studie (Abstract 3 der ASCO Berichte 1) handelt es sich um Phase II
eines randomisierten Tests von BSI-201, einem...]]>https://www.globenewswire.com/news-release/2009/05/18/1541/0/en/BiPar-Sciences-Investigational-PARP-Inhibitor-BSI-201-to-be-Highlighted-During-ASCO-s-Plenary-Session.html?f=22&fvtc=4&fvtv=7548BiPar Sciences' Investigational PARP Inhibitor, BSI-201, to be Highlighted During ASCO's Plenary Session2009-05-18T17:56:31Z<![CDATA[BSI-201 Phase II Data in Metastatic Triple-Negative Breast Cancer Featured At
ASCO Press Briefing; Study Results Will be Released On Sunday, May 31, 2009, At
8:30 a.m. EDT (Orlando, FL)
BRISBANE, Calif. and PARIS, May 18, 2009 (GLOBE NEWSWIRE) -- Results from a
Phase II clinical trial of BiPar Sciences' -- a wholly-owned sanofi-aventis
subsidiary -- lead PARP inhibitor, BSI-201, will be a featured oral plenary
presentation at the 45th annual meeting of the American Society of...]]>https://www.globenewswire.com/news-release/2009/05/18/1541/0/fr/BSI-201-le-nouveau-inhibiteur-PARP-de-BiPar-Sciences-sera-un-moment-fort-de-la-s%C3%A9ance-pl%C3%A9ni%C3%A8re-du-congr%C3%A8s-annuel.html?f=22&fvtc=4&fvtv=7548BSI-201, le nouveau inhibiteur PARP de BiPar Sciences, sera un moment fort de la séance plénière du congrès annuel2009-05-18T17:56:31Z<![CDATA[Les données de phase II du BSI-201 dans le cancer du sein métastatique triple
négatif seront présentées lors d'une conférence de presse officielle de l'ASCO
et intégrées au programme de formation « Best of ASCO » : RÉSULTATS DE L'ÉTUDE
SOUS EMBARGO JUSQU'AU DIMANCHE 31 MAI 08h30 EDT (Heure d'ORLANDO, Floride,
États-Unis)
Les résultats d'un essai clinique de phase II de BiPar Sciences, filiale à 100
% de sanofi-aventis, sur l'inhibiteur PARP BSI-201, feront l'objet d'une
présentation...]]>https://www.globenewswire.com/news-release/2009/05/18/397820/165654/en/BiPar-Sciences-Investigational-PARP-Inhibitor-BSI-201-to-be-Highlighted-During-ASCO-s-Plenary-Session.html?f=22&fvtc=4&fvtv=7548BiPar Sciences' Investigational PARP Inhibitor, BSI-201, to be Highlighted During ASCO's Plenary Session2009-05-18T17:21:08Z<![CDATA[BSI-201 Phase II Data in Metastatic Triple-Negative Breast Cancer Featured At ASCO Press Briefing; Study Results Will be Released On Sunday, May 31, 2009, At 8:30 a.m. EDT (Orlando, FL) BRISBANE, Calif. and PARIS, May 18, 2009 (GLOBE NEWSWIRE) -- Results from a Phase II clinical trial of BiPar Sciences' -- a wholly-owned sanofi-aventis subsidiary -- lead PARP inhibitor, BSI-201, will be a featured oral plenary presentation at the 45th annual meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL.
]]>https://www.globenewswire.com/news-release/2009/04/15/395570/163085/en/Sanofi-aventis-to-Acquire-BiPar-Sciences-a-US-Biopharmaceutical-Company.html?f=22&fvtc=4&fvtv=7548Sanofi-aventis to Acquire BiPar Sciences, a US Biopharmaceutical Company2009-04-15T07:01:00Z<![CDATA[First-in-Class Oncology Medicine Will Provide New Treatment Option While Adding to the Company's Late Stage Development Portfolio BRISBANE, Calif. and PARIS, April 15, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) announced today that it has signed a binding agreement for the acquisition of BiPar Sciences, Inc. ("BiPar"), a privately held US biopharmaceutical company, developing novel tumor-selective approaches for the treatment of different types of cancers.
]]>https://www.globenewswire.com/news-release/2009/02/03/391942/158837/en/BiPar-Sciences-to-Present-At-the-11th-Annual-BIO-CEO-Investor-Conference-in-New-York-City.html?f=22&fvtc=4&fvtv=7548BiPar Sciences to Present At the 11th Annual BIO CEO & Investor Conference in New York City2009-02-03T14:30:00Z<![CDATA[Presentation Scheduled for 11:30 am EST On Monday, February 9, 2009 BRISBANE, Calif., Feb. 3, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that President and Chief Executive Officer Hoyoung Huh, M.D., Ph.D., will present information on BiPar's development programs and product pipeline, including the latest information on the company's lead product candidate, BSI-201 which is in randomized Phase 2 clinical trials in triple negative breast cancer, at the 2009 BIO CEO & Investor Conference 2009 located in New York City, NY.
]]>https://www.globenewswire.com/news-release/2009/01/12/390771/157477/en/BiPar-Sciences-Raises-20-Million-to-Advance-Clinical-Programs.html?f=22&fvtc=4&fvtv=7548BiPar Sciences Raises $20 Million to Advance Clinical Programs2009-01-12T14:00:00Z<![CDATA[Combination of Equity and Venture Debt Doubles Existing Cash Resources BRISBANE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today it has raised $20 million from a combination of equity capital and venture debt financing, more than doubling BiPar's cash resources. Participating in the round were existing equity investors Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners, along with venture-debt lender Lighthouse Capital Partners.
]]>https://www.globenewswire.com/news-release/2009/01/07/390549/157205/en/BiPar-Sciences-to-Present-At-the-27th-Annual-JP-Morgan-Healthcare-Conference-in-San-Francisco.html?f=22&fvtc=4&fvtv=7548BiPar Sciences to Present At the 27th Annual JP Morgan Healthcare Conference in San Francisco2009-01-07T14:00:00Z<![CDATA[Presentation Scheduled for 12 Noon PT On Thursday, January 15, 2009 BRISBANE, Calif., Jan. 7, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that Hoyoung Huh, M.D., Ph.D., BiPar's president and chief executive officer, will present information on BiPar's development programs and product pipeline, including the company's lead product candidate, BSI-201, which is in Phase 2 clinical trials, at the 27th Annual JP Morgan Healthcare Conference in San Francisco, CA.
]]>